

Jignesh P Patel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9191043/publications.pdf>

Version: 2024-02-01

60
papers

1,389
citations

393982

19
h-index

344852

36
g-index

61
all docs

61
docs citations

61
times ranked

2050
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism. <i>Circulation</i> , 2015, 132, 194-204.	1.6	213
2	In Vitro Interaction of the HIV Protease Inhibitor Ritonavir with Herbal Constituents: Changes in P-gp and CYP3A4 Activity. <i>American Journal of Therapeutics</i> , 2004, 11, 262-277.	0.5	133
3	Anticoagulating obese patients in the modern era. <i>British Journal of Haematology</i> , 2011, 155, 137-149.	1.2	86
4	Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 597-605.	1.0	85
5	Complimentary and alternative medicine use among patients starting warfarin. <i>British Journal of Haematology</i> , 2005, 130, 777-780.	1.2	75
6	Adherence to long-term anticoagulation treatment, what is known and what the future might hold. <i>British Journal of Haematology</i> , 2016, 174, 30-42.	1.2	55
7	Heavy menstrual bleeding on rivaroxaban. <i>British Journal of Haematology</i> , 2016, 173, 314-315.	1.2	53
8	Population Pharmacokinetics of Enoxaparin During the Antenatal Period. <i>Circulation</i> , 2013, 128, 1462-1469.	1.6	48
9	The impact of body weight on rivaroxaban pharmacokinetics. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 180-187.	1.0	44
10	An outpatient parenteral antibiotic therapy (OPAT) map to identify risks associated with an OPAT service. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 177-183.	1.3	42
11	Managing direct oral anticoagulants in patients undergoing dentoalveolar surgery. <i>British Dental Journal</i> , 2017, 222, 245-249.	0.3	38
12	Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2296-2307.	1.9	37
13	Traditional Anticoagulants and Hair Loss: A Role for Direct Oral Anticoagulants? A Review of the Literature. <i>Drugs - Real World Outcomes</i> , 2016, 3, 1-6.	0.7	34
14	Progress in the monitoring of direct oral anticoagulant therapy. <i>British Journal of Haematology</i> , 2019, 184, 912-924.	1.2	33
15	Transport of HIV-protease inhibitors across 1 alpha,25di-hydroxy vitamin D3-treated Calu-3 cell monolayers: modulation of P-glycoprotein activity. <i>Pharmaceutical Research</i> , 2002, 19, 1696-1703.	1.7	30
16	Current challenges and future prospects in oral anticoagulant therapy. <i>British Journal of Haematology</i> , 2017, 178, 838-851.	1.2	30
17	Women's views on and adherence to low-molecular-weight heparin therapy during pregnancy and the puerperium. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2526-2534.	1.9	28
18	Venous thromboembolism and women's health. <i>British Journal of Haematology</i> , 2018, 183, 346-363.	1.2	24

#	ARTICLE	IF	CITATIONS
19	Where do we go now with low molecular weight heparin use in obstetric care?. Journal of Thrombosis and Haemostasis, 2008, 6, 1461-1467.	1.9	20
20	Exploration of adherence and patient experiences with DOACs one year after switching from vitamin-K antagonists- insights from the switching study. Thrombosis Research, 2018, 162, 62-68.	0.8	19
21	The current status of bridging anticoagulation. British Journal of Haematology, 2014, 164, 619-629.	1.2	18
22	Associations between illness beliefs, medication beliefs, anticoagulation-related quality of life, and INR control: Insights from the Switching Study. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 497-507.	1.0	17
23	Changes in thrombin generation and D-dimer concentrations in women injecting enoxaparin during pregnancy and the puerperium. BMC Pregnancy and Childbirth, 2014, 14, 384.	0.9	16
24	A UHPLC-MS/MS method to simultaneously quantify apixaban, edoxaban and rivaroxaban in human plasma and breast milk: For emerging lactation studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1144, 122095.	1.2	14
25	Understanding vs. competency: the case of accuracy checking dispensed medicines in pharmacy. Advances in Health Sciences Education, 2010, 15, 735-747.	1.7	13
26	More on normal prothrombin times in the presence of therapeutic levels of rivaroxaban – early experience from King's College Hospital. British Journal of Haematology, 2013, 162, 717-718.	1.2	12
27	Normal prothrombin times in the presence of therapeutic levels of apixaban – in vivo experience from King's College Hospital. British Journal of Haematology, 2015, 169, 152-153.	1.2	12
28	Women's views, adherence and experience with postnatal thromboprophylaxis. Thrombosis Research, 2019, 173, 85-90.	0.8	12
29	Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic. Thrombosis Research, 2021, 197, 192-194.	0.8	11
30	Quality and use of unlicensed vitamin D preparations in primary care in England: Retrospective review of national prescription data and laboratory analysis. British Journal of Clinical Pharmacology, 2021, 87, 1338-1346.	1.1	11
31	Factors influencing the recruitment of lactating women in a clinical trial involving direct oral anticoagulants: a qualitative study. International Journal of Clinical Pharmacy, 2018, 40, 1511-1518.	1.0	9
32	An evaluation of using multi-source feedback (MSF) among junior hospital pharmacists. International Journal of Pharmacy Practice, 2011, 19, 276-280.	0.3	8
33	Attitudes and beliefs that affect adherence to provider-based complementary and alternative medicine: A systematic review. European Journal of Integrative Medicine, 2018, 17, 92-101.	0.8	8
34	What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial. Journal of Thrombosis and Thrombolysis, 2019, 48, 315-322.	1.0	8
35	Managing direct oral anticoagulants in accordance with the Scottish Dental Clinical Effectiveness Programme guidance for patients undergoing dentoalveolar surgery. British Dental Journal, 2022, 232, 547-554.	0.3	8
36	Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations?. Blood, 2020, 136, 1783-1785.	0.6	7

#	ARTICLE	IF	CITATIONS
37	Understanding the Traditional Chinese Medicine (TCM) consultation: Why do patients adhere to treatment?. <i>Complementary Therapies in Clinical Practice</i> , 2020, 39, 101139.	0.7	7
38	New oral anticoagulants: dosing and monitoring. <i>BMJ</i> , The, 2015, 350, h2655-h2655.	3.0	6
39	Early experiences of the mini-PAT (Peer Assessment Tool) amongst hospital pharmacists in South East London. <i>International Journal of Pharmacy Practice</i> , 2010, 17, 123-126.	0.3	5
40	Anticoagulated patient's perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy " study protocol for The Switching Study: a prospective cohort study. <i>BMC Hematology</i> , 2016, 16, 22.	2.6	5
41	Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide. <i>Thrombosis Research</i> , 2019, 176, 36-38.	0.8	5
42	Population pharmacokinetics and dose optimisation of colecalciferol in paediatric patients with chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	5
43	Testing the Traditional Chinese Medicine Consultation Model for Adherence in Complementary and Alternative Medicine. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-13.	0.5	5
44	Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching Study. <i>Thrombosis Research</i> , 2021, 208, 162-169.	0.8	5
45	Re: Pregnancy outcomes in women with mechanical prosthetic heart valves " a prospective descriptive population-based study using the United Kingdom Obstetric Surveillance System (<scp>UKOSS</scp>) data collection system. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 96-96.	1.1	4
46	Rivaroxaban in acute venous thromboembolism: UK prescribing experience. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12607.	1.0	4
47	Sub therapeutic rivaroxaban plasma concentrations following administration via Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes " A note of caution. <i>Thrombosis Research</i> , 2018, 168, 102-103.	0.8	3
48	UK real-world experience of prescribing rivaroxaban for acute venous thromboembolism in obesity: Results from the FIRST Registry. <i>Thrombosis Research</i> , 2021, 197, 16-19.	0.8	3
49	More on enoxaparin thromboprophylaxis in pregnancy: A review of 10 years' experience from King's College Hospital. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 304-308.	1.9	3
50	Adherence to rivaroxaban for the treatment of venous thromboembolism "Results from the FIRST registry. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12614.	1.0	3
51	Early experiences of the mini-PAT (Peer Assessment Tool) amongst hospital pharmacists in south east London. <i>International Journal of Pharmacy Practice</i> , 2009, 17, 123-6.	0.3	3
52	Hypervitaminosis D and nephrocalcinosis: too much of a good thing?. <i>Pediatric Nephrology</i> , 2022, 37, 2225-2229.	0.9	3
53	Prothrombin times in the presence of edoxaban " <i>in vivo</i> experience from King's College hospital. <i>British Journal of Haematology</i> , 2019, 184, 455-456.	1.2	2
54	Mode of Delivery Does Not Influence Postpartum Hypercoagulability Measured by Thrombin Generation or Thromboelastometry. <i>TH Open</i> , 2020, 04, e1-e11.	0.7	2

#	ARTICLE	IF	CITATIONS
55	An international survey of low molecular weight heparin prescribing in the context of antenatal venous thromboembolism. <i>Thrombosis Research</i> , 2021, 200, 99-101.	0.8	2
56	The perils of inhibiting deficient factors. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1535-1536.	1.9	1
57	The First Registry: Follow-up in Rivaroxaban Patients in the Setting of Venous Thromboembolism. <i>Blood</i> , 2015, 126, 4737-4737.	0.6	1
58	ACH-126443 Achillion/Yale University. <i>Current Opinion in Investigational Drugs</i> , 2002, 3, 1580-4.	2.3	1
59	Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis • Reply to Jacobs & Ryan comment. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 872-873.	1.9	0
60	Early experiences of the mini-PAT (Peer Assessment Tool) amongst hospital pharmacists in South East London. <i>International Journal of Pharmacy Practice</i> , 2009, 17, 123-126.	0.3	0